\u3ci\u3eMoraxella\u3c/i\u3e Spp. Isolated from Field Outbreaks of Infectious Bovine Keratoconjunctivitis: A Retrospective Study of Case Submissions from 2010 to 2013 by Loy, John Dustin & Brodersen, Bruce W.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Papers in Veterinary and Biomedical Science Veterinary and Biomedical Sciences, Department of
2014
Moraxella Spp. Isolated from Field Outbreaks of
Infectious Bovine Keratoconjunctivitis: A
Retrospective Study of Case Submissions from
2010 to 2013
John Dustin Loy
University of Nebraska-Lincoln, jdloy@unl.edu
Bruce W. Brodersen
University of Nebraska-Lincoln, bbrodersen1@unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/vetscipapers
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental
Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons,
Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and
Pathobiology Commons
This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and Biomedical Science by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Loy, John Dustin and Brodersen, Bruce W., "Moraxella Spp. Isolated from Field Outbreaks of Infectious Bovine Keratoconjunctivitis: A
Retrospective Study of Case Submissions from 2010 to 2013" (2014). Papers in Veterinary and Biomedical Science. 277.
http://digitalcommons.unl.edu/vetscipapers/277
Journal of Veterinary Diagnostic Investigation
2014, Vol. 26(6) 761 –768
© 2014 The Author(s)
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1040638714551403
jvdi.sagepub.com
Full Scientific Report
Introduction
Infectious bovine keratoconjunctivitis (IBK), also known as 
pinkeye, is a common and costly eye disease of domestic 
cattle.28,29 Cattle with IBK demonstrate a variety of clinical 
signs, including increased tear production, sensitivity to 
light, and ultimately corneal swelling that progresses into 
corneal ulceration and possible blindness.2 Very little is 
understood about the impacts of IBK on animal welfare30; 
however, pain assessment studies demonstrate that it is a 
painful and irritating condition.13 Economic losses in the 
beef industry can be tremendous, where a 15.9-kg loss in 
weaning weight per head has been estimated.20 Midwestern 
U.S. beef herds report that IBK is endemic in nearly 50% of 
herds with a prevalence of 8.75 out of 100 cattle affected.29 
Adequate and timely treatment of acute IBK with antimicro-
bial therapy is frequently challenging due to many animals 
being remotely pastured or grazed during peak occurrence in 
the summer months.26
The principal etiologic agent for IBK is the Gram-nega-
tive bacterium Moraxella bovis.19 One of the major virulence 
factors of M. bovis is a secreted cytotoxin that has been 
shown to reproduce IBK lesions in calves.10 This toxin is a 
repeats-in toxin (RTX), which forms pores in the membranes 
of target host cells causing lysis and cell death.11 Moraxella 
bovoculi, a newly described species in the genus Moraxella, 
has been isolated and characterized in association with IBK 
in the absence of M. bovis.9 Additional evidence for the role 
of M. bovoculi in the causation of IBK includes secretion of 
a RTX class cytotoxin similar to that of M. bovis.6 However, 
studies evaluating vaccine efficacy show a decrease in inci-
dence of IBK neither when M. bovoculi was included in an 
autogenous vaccine formulation15 nor when subunit M. 
bovoculi cytotoxin was used as a vaccine in calves.8 Direct 
inoculation of M. bovoculi into scarified calf corneas does 
not cause IBK lesions, making the direct role of M. bovoculi 
in IBK pathogenesis uncertain.18 The data indicates that 
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Abstract. Infectious bovine keratoconjunctivitis (IBK), also known as pinkeye, is the most costly eye disease of cattle. The 
principal etiologic agent of IBK is the Gram-negative bacterium Moraxella bovis. However, there have been reports of IBK 
outbreaks associated with Moraxella bovoculi. A retrospective study of IBK diagnostic cases submitted from July 1, 2010 
through October 31, 2013 was conducted. Included in the study were 1,042 Moraxella isolates from 1,538 swabs of lacrimal 
secretions collected from 282 herds from 30 U.S. states. Moraxella isolates were identified to the species level and were 
composed of M. bovoculi (701 isolates), M. bovis (295 isolates), Moraxella ovis (5 isolates), and other Moraxella spp. (41). 
Minimum inhibitory concentrations required for 90% growth inhibition (MIC
90
) was calculated for representative isolates. The
MIC
90
 values for both M. bovis and M. bovoculi were as follows: ampicillin and ceftiofur: ≤0.25 µg/ml; clindamycin: 2 µg/ml;
danofloxacin and enrofloxacin: ≤0.12 µg/ml; florfenicol: 0.5 µg/ml; gentamicin: 1 µg/ml; neomycin: 4 µg/ml; tulathromycin: 
2 µg/ml; and tylosin: 8 µg/ml. The MIC
90
 values for M. bovoculi included the following: chlortetracycline: ≤0.5 µg/ml;
oxytetracycline: 4 µg/ml; penicillin: 0.25 µg/ml; spectinomycin: 32 µg/ml; sulfadimethoxine: >256 µg/ml; tiamulin: 1 µg/
ml; and trimethoprim–sulfamethoxazole: 4 µg/ml. For M. bovis, MIC
90
 values included the following: chlortetracycline and
oxytetracycline: 1 µg/ml; penicillin: ≤0.12 µg/ml; spectinomycin: 16 µg/ml; sulfadimethoxine: ≤256 µg/ml; tiamulin: ≤0.5 µg/
ml; and trimethoprim–sulfamethoxazole: ≤2 µg/ml. The current work describes the frequency of isolation and differences in 
antimicrobial sensitivity observed among Moraxella isolates from case submissions.
Key words: Infectious bovine keratoconjunctivitis; Moraxella bovis; Moraxella bovoculi.
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although M. bovoculi is isolated in cases of IBK, there is no 
direct evidence supporting a causal role, and temporal asso-
ciations of M. bovoculi and correlation of eye colonization 
with disease have been difficult to determine.21 In order to 
further characterize the microbial populations present in 
bovine eyes during outbreaks of IBK, a retrospective study 
was undertaken to assess the composition of Moraxella spp. 
in a large number of diagnostic submissions, as well as to 
assess the antimicrobial susceptibility patterns to selected 
antimicrobial agents of representative isolates from diagnos-
tic submissions.
Materials and methods
Samples included in the current study were comprised of 
diagnostic laboratory submissions received from July 1, 
2010 to October 31, 2013 that had been submitted as diag-
nostic cases to the Nebraska Veterinary Diagnostic Center 
(Lincoln, Nebraska). Data was extracted from a laboratory 
information management software system (LIMS) that 
includes all diagnostic submissions over the time period. A 
subset of data was extracted into spreadsheet software 
including case submissions of swabs of lacrimal secretions 
collected from bovine eyes during cases of IBK in beef or 
dairy herds. For some diagnostic submissions, a specific 
state or geographic region where the herd was located in 
which the sample was taken was not included on the submis-
sion information. Herd data was based on unique accession 
numbers assigned to each case. Individual data was deter-
mined based on a unique individual identification number 
present on a case submission form. Isolation of Moraxella 
spp. on eye swabs was conducted by trained technicians fol-
lowing standard operating procedures in an American Asso-
ciation of Veterinary Laboratory Diagnosticians (AAVLD) 
fully accredited laboratory. Data entry into LIMS was per-
formed by the technician, and results were reviewed by a 
laboratory manager and a case coordinator for accuracy. The 
protocol used by all trained technicians in the laboratory at 
the time period, to determine if viable Moraxella spp. were 
present in the samples, was as follows: Swabs were streaked 
onto tryptic soy agar containing 5% sheep’s blood and incu-
bated for 18–24 hr at 37°C with 5% CO
2
 supplementation.
Bacterial colonies with morphology consistent with mem-
bers of the genus Moraxella were further screened for oxi-
dase production. Colonies positive for oxidase production 
were then subjected to Gram staining and were subcultured 
for purity. All subcultured organisms that were characterized 
as Gram-negative rods or coccobacilli by Gram stain were 
subjected to molecular speciation. Isolates were subse-
quently identified as M. bovis, M. bovoculi, or Moraxella 
ovis based on a polymerase chain reaction (PCR) assay and a 
subsequent restriction fragment length polymorphism analy-
sis that targets the 16S-23S intergenic spacer region in com-
bination with phenotypic tests as needed.4 Some isolates 
could not be definitively identified based on PCR data and 
phenotypic data, and were categorized as Moraxella sp.
For PCR testing, genomic DNA was extracted from 24-hr 
subculture growth by picking out several well-isolated colo-
nies with a sterile stick and then resuspending the colonies 
into 100 µl of nuclease-free water to a 1–2 McFarland stan-
dard turbidity. Cell suspensions were boiled at 100°C for 10 
min to lyse bacterial cells. Cell debris was clarified by cen-
trifugation at 15,700 × g for 2 min. Extracted nucleic acid 
was subjected to PCR using primersa ISRdown 
(5′-GTGAAGTCGTAACAAGGTAGCCGT-3′) and ISRup 
(5′-ACCGACGCTTATCGCAGGCTATCA-3′).4 The PCR 
master mixb consisted of 50 µl, which contained nuclease-
free H
2
O (32.1 µl), 5.0 µl of 10× reaction buffer, 4.0 µl of
MgCl
2
 (50 mM), 0.5 µl of deoxyribonucleotide triphosphates
(100 mM), 2.5 µl of ISRup (10 µM), 2.5 µl of ISRdown (10 
µM), 0.4 µl of Taq polymerase (5 U/µl), and 3.0 µl of tem-
plate DNA. The PCR reactions were subjected to thermocy-
cling under the following conditions; 95°C for 60 sec, then 
40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 
30 sec and a final extension of 72°C for 7 min. Amplicons 
were then digested with restriction endonuclease AfaIc and 
subjected to a 60-min digestion at 37°C. Digested DNA (15 
µl) was resolved using capillary gel electrophoresis.d Inter-
pretation of molecular weight fragments corresponding to 
M. bovoculi, M. ovis, and M. bovis was 450- and 150-bp, 
600-bp, and 650-bp fragments, respectively.
As part of the diagnostic workup of each case submission, 
representative isolates were selected on a herd level based on 
similar colony growth characteristics and PCR speciation. 
The representative isolates were then subjected to antimicro-
bial sensitivity testing. Because of the small number of M. 
ovis isolates and possible diversity within the Moraxella sp. 
isolated, these organisms were excluded from the antimicro-
bial susceptibility analysis. To conduct in vitro antimicrobial 
sensitivity, a broth microdilution system was used following 
Clinical Laboratory Standards Institute (CLSI) guidelines.12 
Several colonies of pure culture were suspended into 10 ml 
of sterile demineralized water to a 0.5 McFarland standard 
and vortexed to ensure uniform resuspension. Inoculation 
density was confirmed using a calibrated nephelometer. A 
10-µl aliquot of the resuspended organism was then inocu-
lated into 11 ml of sterile inoculation media and vortexed to 
ensure uniform resuspension. A 100-µl aliquot of culture per 
well was then inoculated into bovine and/or porcine antimi-
crobial susceptibility panelse with an autoinoculator. Sam-
ples were incubated at 35°C for 18 hr without carbon dioxide 
supplementation and were read automatically with the mini-
mal inhibitory concentration (MIC) determined using an 
automated system.f The auto-read values were confirmed 
manually by observation as necessary. Quality control organ-
isms used for assays include Staphylococcus aureus (ATCC 
29213), Enterococcus faecalis (ATCC 29212), and Esche-
richia coli (ATCC 25922). No specific CLSI-approved inter-
pretative criteria exist for Moraxella spp. in cattle, therefore 
interpretive criteria established for bovine respiratory dis-
ease or other Gram-negative veterinary isolates as available 
were used, with organisms classified as susceptible (S), 
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intermediate (I), or resistant (R; Table 1).12 Breakpoints were 
not available for neomycin and tylosin. For trimethoprim–
sulfamethoxazole and sulfadimethoxine only a single drug 
concentration was tested. Percent susceptibility (% suscepti-
ble) was determined by dividing the number of organisms 
with MIC values that fell into a susceptible MIC breakpoint 
(numerator) by the total tested (denominator) and multiply-
ing by 100. The MIC
50
 and MIC
90
 values were defined as the
concentration of antibiotic that was capable of inhibiting 
growth of 50% and 90% of total tested isolates.
Results
A total of 1,538 samples were included in the data set. Of 
these, 600 had no growth of Moraxella spp. or were too con-
taminated with overgrowth to determine if there were Morax-
ella organisms present in the specimen. Out of this total, 938 
swabs had growth of 1 or more Moraxella spp., and the total 
number of isolates subjected to identification was 1,042 as 
some had multiple species present. Submitted samples 
included case submissions from cases of IBK in 30 states. 
Submissions from 29 out of 30 states had at least 1 Morax-
ella sp. isolated. The number of submitted samples on a 
state-by-state basis that contained at least 1 Moraxella spp. 
isolated as well as the number of herds from which these 
samples originated, is indicated (Fig. 1). For 261 herds, geo-
graphic information was sufficient to determine the state of 
origin for the submission. On individual animal level 938 
submissions were identified. The frequency of isolation of 
Moraxella in individuals included: M. bovis: 193; M. bovoc-
uli: 600; M. ovis: 4; Moraxella sp.: 37; M. bovis and M. 
bovoculi: 99; M. bovoculi and Moraxella sp.: 1; M. bovoculi 
and M. ovis: 1; M. bovis and Moraxella sp.: 3 (Table 2).
On a herd level, 282 total herds were identified. The fre-
quency of isolation of Moraxella spp. in herds included: M. 
bovis: 18; M. bovoculi: 140; M. ovis: 2; Moraxella sp.: 7; M. 
bovis and M. bovoculi: 102; M. bovoculi and Moraxella sp.: 
2; M. bovoculi and M. ovis: 1; M. bovoculi and M. ovis: 1; M. 
bovis and Moraxella sp.: 1; M. bovis, M. bovoculi, and M. 
ovis: 1 (Table 2).
For M. bovoculi, 213 total isolates were subjected to MIC 
testing against 18 antimicrobials with a range of concentra-
tions (Table 1). MIC
90
 values were as follows: ampicillin,
≤0.25 µg/ml; ceftiofur, ≤0.25 µg/ml; chlortetracycline, ≤0.5 
µg/ml; clindamycin, 2 µg/ml; danofloxacin and enrofloxa-
cin, ≤0.12 µg/ml; florfenicol, 0.5 µg/ml; gentamicin, 1 µg/
ml; neomycin and oxytetracycline, 4 µg/ml; penicillin, 0.25 
µg/ml; spectinomycin, 32 µg/ml; sulfadimethoxine, >256 
µg/ml; tiamulin, 1 µg/ml; trimethoprim–sulfamethoxazole, 4 
µg/ml; tulathromycin, 2 µg/ml; and tylosin, 8 µg/ml (Table 
3). The total susceptible phenotypes observed for M. bovoc-
uli were as follows: ampicillin, 99%; ceftiofur, 100%; chlor-
tetracycline, 93%; clindamycin, 11%; danofloxacin, 98%; 
enrofloxacin, 98%; florfenicol, 92%; gentamicin, 98%; neo-
mycin, not determined (ND); oxytetracycline, 85%; penicil-
lin, 96%; spectinomycin, 86%; sulfadimethoxine, 86%; 
Table 1. Selected antimicrobial drugs utilized in broth microdilution testing for minimum inhibitory concentrations, the range 
of concentrations evaluated for each antimicrobial, and interpretive criteria (susceptible, intermediate, or resistant) applied to each 
antimicrobial tested.
Antimicrobial
Concentration(s) tested 
(µg/ml) Susceptible Intermediate Resistant
Ampicillin 0.25–16 ≤0.5 1 ≥2
Ceftiofur 0.25–8 ≤2 4 ≥8
Chlortetracycline 0.5–8 ≤2 4 ≥8
Clindamycin 0.25–16 ≤0.5 1–2 ≥4
Danofloxacin 0.12–1 ≤0.25 * *
Enrofloxacin 0.12–2 ≤0.25 0.5–1 ≥2
Florfenicol 0.25–8 ≤2 4 ≥8
Gentamicin 1–16 ≤2 4 ≥8
Neomycin 4–32 * * *
Oxytetracycline 0.5–8 ≤2 4 ≥8
Penicillin 0.12–8 ≤0.25 0.5 ≥1
Spectinomycin 8–64 ≤32 64 ≥128
Sulfadimethoxine 256 ≤256 >256
Tiamulin 0.5–32 ≤16 ≥32
Tilmicosin 4–64 ≤8 16 ≥32
Trimethoprim–sulfamethoxazole 2/38† <2/38 ≥2/38
Tulathromycin 1–64 ≤16 32 ≥64
Tylosin 0.5–32 * * *
* No interpretive criteria available.
† A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.
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tiamulin, 99%; tilmicosin, 92%; trimethoprim–sulfamethox-
azole, 87%; tulathromycin, 92%; and tylosin, ND (Table 3).
For M. bovis, 106 total isolates were subjected to MIC 
testing against 18 antimicrobials with a range of concentra-
tions (Table 1). The MIC
90
 values were as follows: ampicil-
lin, ≤0.25 µg/ml; ceftiofur, ≤0.25 µg/ml; chlortetracycline, 1 
µg/ml; clindamycin, 2 µg/ml; danofloxacin and enrofloxa-
cin, ≤0.12 µg/ml; florfenicol, 0.5 µg/ml; gentamicin, 1 µg/
ml; neomycin, 4 µg/ml; oxytetracycline, 1 µg/ml; penicillin, 
≤0.12 µg/ml; spectinomycin, 16 µg/ml; sulfadimethoxine, 
≤256 µg/ml; tiamulin, ≤0.5 µg/ml; trimethoprim–sulfa-
methoxazole, ≤2 µg/ml; tulathromycin, 2 µg/ml; and tylosin, 
8 µg/ml (Table 4). The total susceptible phenotypes observed 
for M. bovis were as follows: ampicillin, 99%; ceftiofur, 
100%; chlortetracycline, 91%; clindamycin, 21%; danoflox-
acin, 100%; enrofloxacin, 100%; florfenicol, 100%; genta-
micin, 100%; neomycin, ND; oxytetracycline, 96%; 
penicillin, 99%; spectinomycin, 100%; sulfadimethoxine, 
98%; tiamulin, 99%; tilmicosin, 100%; trimethoprim–sulfa-
methoxazole, 98%; tulathromycin, 94%; and tylosin, ND 
(Table 4).
Discussion
While previous data indicated that M. bovoculi is isolated in 
association with outbreaks of IBK in the absence of M. 
bovis,9,21 the current study has characterized the composition 
of Moraxella isolates associated with IBK from a large num-
ber of geographically diverse case submissions in the United 
States. Other authors have characterized genetic diversity 
using fingerprinting among Moraxella spp. in other countries 
but have not examined these on a herd or individual animal 
level.27 It was observed in the current study that M. bovoculi 
Table 2. Profile of Moraxella spp. isolated from lacrimal 
secretion swab cultures (n = 1,042).*
No. of  
herds  
yielding the 
indicated species
No. of 
individuals 
yielding the 
indicated species
Species isolated (1) (2)
Moraxella bovis 18 193
Moraxella bovoculi 140 600
Moraxella ovis 2 4
Moraxella sp. 7 37
M. bovis and M. bovoculi 102 99
M. bovoculi and Moraxella 
sp.
2 1
M. bovoculi and M. ovis 1 1
M. bovis and Moraxella 
sp.
2 3
M. bovis, M. ovis, and 
M. bovoculi
1 0
* The number of herds with the corresponding species composition of
isolated organisms is indicated in column (1). Column (2) indicates the 
number of herds with the corresponding species composition isolated from 
samples.
Figure 1. Number and state-by-state distribution of case submissions that at least 1 Moraxella spp. was isolated from bovine ocular 
swabs. States with at least 1 Moraxella isolate included in the analysis are shaded in dark gray. Numbers on the state indicates the total 
positive case submissions received in the period, and the number in parentheses indicates the number of positive herds included in each state 
over the period from July 1, 2010 to October 31, 2013.
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was the only Moraxella sp. isolated from the majority of case 
submissions, when evaluated at either the herd or individual 
level. These findings were unexpected, given that M. bovis 
has been isolated from experimentally infected calves up to 
54 days following inoculation, and thus it was thought that 
M. bovis would be the predominant organism isolated in 
association with IBK outbreaks.17 However, recovery of M. 
bovis may be variable as pathogenesis studies have shown 
that M. bovis was not observed on the conjunctival surface, 
using light microscopy, 10-hr postinoculation when intro-
duced in gnotobiotic calves.23 Other studies have shown that 
M. bovoculi can be isolated from ulcers in calves experimen-
tally inoculated with M. bovis.18 Epidemiologic investiga-
tions have also failed to establish a temporal relationship 
between prior exposure and clinical IBK outbreaks with iso-
lations of M. bovoculi.21 Analysis of the speciation data in 
the current study indicates that M. bovoculi is present and 
viable in most of the submissions in higher numbers than M. 
bovis. Moraxella bovis, when cultured, was frequently iso-
lated in association with M. bovoculi, and was the sole 
Moraxella spp. isolated in only 18 of the 282 herd submis-
sions. The generally accepted method for sample collection 
for IBK culture is to place the swab in the ventral conjuncti-
val sac to sample lacrimal secretions. Differences and vari-
ability in and among sampling methods and timing of 
collection may result in samples that may not be representa-
tive of all organisms present in the eye conjunctiva. Addi-
tionally, the isolation of M. ovis from only 5 swabs indicates 
that this species, at least in this set of samples, is likely not 
significantly contributing to IBK in cattle.
Previous studies have evaluated antimicrobial resistance 
patterns in M. bovis and M. bovoculi in smaller collections of 
isolates individually.5,25 Additionally, a study assessing the 
diversity of Moraxella spp. in IBK cases from Uruguay eval-
uated antimicrobial susceptibility; however, the methods uti-
lized disk diffusion and did not measure zone sizes for 
interpretation, as recommended by the CLSI, and did not use 
minimum inhibitory concentration testing making compari-
son with this data difficult.27 The antimicrobial susceptibility 
data from the present study, for M. bovoculi, is similar to a 
study that examined 57 isolates from California.5 However, 
there were some differences observed. Moraxella bovoculi 
isolates showed a reduced level of in vitro susceptibility to 
the tetracycline class drugs, where the MIC
90
 for oxytetracy-
cline was found to be 4 µg/ml instead of 1 µg/ml. This is a 
four-fold increase in MIC
90
 value over the previously pub-
lished data.6 Contrastingly, the MIC
90
 for M. bovis against 
oxytetracycline was previously reported as 32 µg/ml,25 
whereas a much lower MIC
90
 of 1 µg/ml was found in the 
current study. The MIC
90
 of tulathromycin for both M. bovis 
Table 3. Count of Moraxella bovoculi isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested. 
Additionally, the MIC required to inhibit 50% and 90% (MIC
50
 and MIC
90
, respectively) of each isolate as well as the total percentage of 
M. bovoculi isolates that were susceptible to each antibiotic are included (n = 213 isolates).
Antimicrobial
MIC (µg/ml)
MIC
50
MIC
90
% susceptible0.12 0.25 0.5 1 2 4 8 16 32 64 ≤256 >256
Ampicillin 211 2 ≤0.25 ≤0.25 99
Ceftiofur 207 4 ≤0.25 ≤0.25 100
Chlortetracycline 185 11 2 11 4* ≤0.5 ≤0.5 93
Clindamycin 11 13 119 62 4 2 2* 1 2 11
Danofloxacin 207 2 4* ≤0.12 ≤0.12 98
Enrofloxacin 207 2 4* ≤0.12 ≤0.12 98
Florfenicol 28 164 2 2 11 4* 0.5 0.5 92
Gentamicin 204 4 2 2 1 1 98
Neomycin 200 9 2 2 4 4 †
Oxytetracycline 153 26 2 11 19* ≤0.5 4 85
Penicillin 183 21 4 2 2 ≤0.12 0.25 96
Spectinomycin 45 142 9 17* 16 32 92
Sulfadimethoxine 183 30 ≤256 >256 86
Tiamulin 181 26 2 2 2 ≤0.5 1 99
Tilmicosin 179 17 2 11 4 ≤4 8 92
Trimethoprim–
sulfamethoxazole‡
185 28§ ≤2 4 87
Tulathromycin 179 13 4 6 6 ≤1 2 92.0
Tylosin 2 2 147 70 4 8 †
* Endpoint of > for the MIC indicated.
† No interpretive criteria available.
‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.
§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.
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and M. bovoculi fell within the susceptible range of 2 µg/ml. 
However, there were 16 isolates of M. bovoculi with MIC 
values of 8 or greater for tulathromycin, with 6 of these iso-
lates with MIC values of 64 µg/ml or greater. This is impor-
tant to note, as oxytetracycline and tulathromycin are 2 
antimicrobials with label claims for treatment of IBK associ-
ated with M. bovis.
Other antimicrobial drugs have been reported to be effec-
tive at treating IBK, including penicillin,1,3 cloxacillin 
benzathine,17 ceftiofur,14 clindamycin,24 florfenicol,7 and 
tilmicosin.31 A systematic review of randomized clinical trials 
examining IBK pharmacological studies indicated that direct 
comparisons between therapies were lacking, making drug 
comparisons challenging.22 Evaluation of antimicrobial effi-
cacy for therapy cannot be determined based on susceptibility 
patterns; however, in vitro testing of M. bovis and M. bovoculi 
indicate susceptibility to most of the antimicrobials, with 
MIC
90
 values falling into the susceptible category. The lowest
percentage of susceptibility was seen with clindamycin; how-
ever, a significant number of organisms fell in the intermedi-
ate interpretive category for clindamycin (70 and 17 for M. 
bovoculi and M. bovis, respectively) making the number of 
isolates in the resistant category quite low, with a MIC
90
 of 2
µg/ml for both Moraxella species. While previous reports of 
antimicrobial susceptibility testing have shown elevated 
resistance to penicillin for M. bovoculi (12.3%),5 data in the 
present study showed only a 4% level of resistance. The anti-
microbial resistance patterns appear similar between geo-
graphically distinct M. bovis and M. bovoculi isolates, 
indicating that infections with either or both organisms show 
similar susceptibility patterns as previously noted.5 However, 
it should be noted that there are some small differences, as the 
MIC
90
 of M. bovoculi for oxytetracycline was higher than for
M. bovis (4 µg/ml compared with 1 µg/ml).
Differences in these susceptibility patterns may be indica-
tive of regional preference for antimicrobial usage to treat 
IBK, and the emergence of these patterns may be based on 
selective pressure. Other factors that may influence this dif-
ference include transmission of resistance genotypes on a 
regional level, as all of the previously tested M. bovoculi iso-
lates were from California and the current study was biased 
toward Midwestern U.S. states but included other states. 
Antimicrobial treatment prior to sampling was unable to be 
determined as this was not routinely included in the case his-
tories on the submissions forms. However, prior treatment 
with antimicrobials may affect in vitro susceptibility data, 
and knowledge of a treatment history may enable more anal-
ysis of these patterns.
In conclusion, M. bovoculi is the most prevalent and fre-
quent of the Moraxella sp. isolated in IBK cases in cattle 
Table 4. Count of Moraxella bovis isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested. Additionally, 
the MIC required to inhibit 50% and 90% (MIC
50
 and MIC
90
, respectively) of each isolate as well as the total percentage of M. bovis
isolates that were susceptible to each antibiotic are included (n = 106 isolates).
Antimicrobial
MIC (µg/ml)
MIC
50
MIC
90
% 
susceptible0.12 0.25 0.5 1 2 4 8 16 32 64 ≤256 >256
Ampicillin 105 1 ≤0.25 ≤0.25 99
Ceftiofur 104 2 ≤0.25 ≤0.25 100
Chlortetracycline 93 2 1 10* ≤0.5 1 91
Clindamycin 22 67 15 2 1 2 21
Danofloxacin 100 6 ≤0.12 ≤0.12 100
Enrofloxacin 103 3 ≤0.12 ≤0.12 100
Florfenicol 72 33 1 0.5 0.5 100
Gentamicin 106 1 1 100
Neomycin 105 1 4 4 †
Oxytetracycline 94 8 1 3 ≤0.5 1 96
Penicillin 99 6 1 ≤0.12 ≤0.12 99
Spectinomycin 98 8 16 16 100
Sulfadimethoxine 104 2 ≤256 ≤256 98
Tiamulin 98 6 1 1 ≤0.5 ≤0.5 99
Tilmicosin 95 11 ≤4 8 100
Trimethoprim–
sulfamethoxazole‡
104 2§ ≤2 ≤2 98
Tulathromycin 104 1 1 6 ≤1 2 94
Tylosin 8 21 45 29 3 4 8 †
* Endpoint of > for the MIC indicated.
† No interpretive criteria available.
‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.
§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.
Retrospective study of Moraxella spp. associated with IBK 767
submitted to the Nebraska Veterinary Diagnostic Center on 
both individual and herd levels. Over 600 of the 1,042 iso-
lates tested were M. bovoculi. In nearly half (102/282) of the 
herds tested, both M. bovoculi and M. bovis were isolated 
from 1 or more animals in those herds. The frequency of co-
isolations may indicate that M. bovoculi may be serving as an 
opportunistic agent or colonizing eyes in conjunction with 
M. bovis, which has been shown experimentally to induce 
characteristic ulcers in gnotobiotic calves.23 Further work 
should be conducted to elucidate the temporal factors and 
role of coinfections with M. bovoculi and M. bovis in IBK 
pathogenesis that would enable further interpretation of this 
data.
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